To address these challenges, a pH-sensitive PEG–PGA-coated, PD-L1/EGFR-targeted SLN system was engineered to co-deliver the proteostasis modulator CB, the immune-regulatory miR-142, and the TLR7 agonist R. The optimized formulations exhibited hydrodynamic diameters below 200 nm, a narrow PDI (~0.15), and encapsulation efficiencies above 80% (Table 1), parameters favorable for passive and receptor-mediated tumor accumulation. The gene discussed is TLR7; the disease is neoplasm.